Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP NASDAQ:HLVX NASDAQ:QTTB NASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$9.31+0.4%$8.32$4.64▼$61.89$113.43M3.2122,735 shs122,153 shsHLVXHilleVax$2.04-3.3%$2.00$1.34▼$2.17$105.80M0.76110,492 shs71,883 shsQTTBQ32 Bio$2.00-9.9%$1.87$1.35▼$53.79$27.08MN/A3.80 million shs291,573 shsSAVACassava Sciences$2.12+1.0%$2.11$1.15▼$42.20$101.45M-2.05794,894 shs547,139 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals+0.43%+0.54%+20.13%+19.51%-84.35%HLVXHilleVax-3.32%-5.12%-3.32%+4.08%+11.48%QTTBQ32 Bio-9.91%-9.50%+38.89%+21.95%-94.75%SAVACassava Sciences+0.95%-9.79%+5.47%+31.68%-90.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBPCorbus Pharmaceuticals4.7393 of 5 stars4.63.00.04.73.22.50.6HLVXHilleVax1.8451 of 5 stars1.05.00.00.02.13.31.3QTTBQ32 Bio1.4157 of 5 stars3.12.00.00.00.01.70.6SAVACassava Sciences3.5719 of 5 stars3.33.00.04.70.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 3.10Buy$49.38430.34% UpsideHLVXHilleVax 2.00Hold$2.00-1.96% DownsideQTTBQ32 Bio 2.25Hold$12.17508.33% UpsideSAVACassava Sciences 2.50Moderate Buy$54.502,470.75% UpsideCurrent Analyst Ratings BreakdownLatest QTTB, SAVA, CRBP, and HLVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$28.007/12/2025CRBPCorbus PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025CRBPCorbus PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.005/7/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.005/7/2025CRBPCorbus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $40.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$11.69 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/AQTTBQ32 Bio$1.16M21.03N/AN/A$0.47 per share4.26SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)HLVXHilleVax-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)QTTBQ32 Bio-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)SAVACassava Sciences-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)Latest QTTB, SAVA, CRBP, and HLVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HLVXHilleVax-$0.14N/AN/AN/AN/AN/A8/14/2025Q2 2025QTTBQ32 Bio-$1.14N/AN/AN/AN/AN/A8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.35N/AN/AN/AN/AN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/A5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A11.8211.82HLVXHilleVaxN/A25.3225.32QTTBQ32 Bio1.684.714.71SAVACassava SciencesN/A9.089.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%HLVXHilleVax86.42%QTTBQ32 Bio31.32%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.60%HLVXHilleVax24.90%QTTBQ32 Bio40.00%SAVACassava Sciences2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4012.24 million11.80 millionOptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableQTTBQ32 Bio3912.20 million7.32 millionN/ASAVACassava Sciences3048.31 million47.15 millionOptionableQTTB, SAVA, CRBP, and HLVX HeadlinesRecent News About These CompaniesGallacher Capital Management LLC Decreases Stock Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA)July 23, 2025 | marketbeat.comSAVA - Cassava Sciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMCassava Sciences presents poster at TSC 2025 on SimufilamJune 30, 2025 | msn.comCassava Presents Promising Preclinical Simufilam Data at TSC Alliance MeetingJune 30, 2025 | globenewswire.comSAVA Stock Price for Cassava Sciences Inc - MorningstarJune 28, 2025 | morningstar.comMWhy cassava could be a great addition to a balanced dietJune 26, 2025 | msn.comCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava partners with Zindi to give African AI developers better toolsMay 15, 2025 | techzim.co.zwTCassava Sciences Inc.May 15, 2025 | barrons.com5 ON YOUR SIDE: Lead levels in cassava flourMay 15, 2025 | kstp.comKCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comCassava Technologies and Zindi collaborate to showcase African A.I. innovationMay 12, 2025 | thezimbabwemail.comTCassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU EcosystemMay 12, 2025 | devdiscourse.comDNew report finds concerning levels of lead in popular cassava itemsMay 12, 2025 | yahoo.comCassava takes next step for African AIMay 12, 2025 | htxt.co.zaHCassava Technologies and Zindi collaborate to showcase African Artificial Intelligence (AI) innovationMay 12, 2025 | zawya.comZCassava Reports Q1 2025 Financials Results, Provides Business UpdateMay 9, 2025 | finance.yahoo.comZindi Teams Up with Cassava to Spotlight African AI TalentMay 6, 2025 | msn.comZindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovationMay 5, 2025 | msn.comCassava Consciousness from The Tamarind Galaxy part twoMay 1, 2025 | modernghana.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTTB, SAVA, CRBP, and HLVX Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$9.31 +0.04 (+0.43%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.34 +0.03 (+0.32%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.HilleVax NASDAQ:HLVX$2.04 -0.07 (-3.32%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.04 0.00 (0.00%) As of 08/1/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Q32 Bio NASDAQ:QTTB$2.00 -0.22 (-9.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.99 -0.01 (-0.50%) As of 08/1/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Cassava Sciences NASDAQ:SAVA$2.12 +0.02 (+0.95%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.13 +0.01 (+0.66%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
